ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sharif Al-Ruzzeh
Samir Shah
David O’Regan
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Ruzzeh, S.
Right arrow Articles by O’Regan, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Ruzzeh, S.
Right arrow Articles by O’Regan, D.
Related Collections
Right arrow Cardiac - other
Right arrowRelated Article

Ann Thorac Surg 2007;83:355
© 2007 The Society of Thoracic Surgeons

Correspondence

Caution With the Use of Recombinant Activated Factor VII in Treating Postoperative Hemorrhage in Cardiac Surgery

Sharif Al-Ruzzeh, PhD, FRCS, Amr Mahmoud, MS, FCARCSI, Samir Shah, MS, FRCS, David O’Regan, MD, FRCS

The Yorkshire Heart Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX United Kingdom

(Email: sharifalruzzeh@hotmail.com).

The first 20% of the full text of this article appears below.

To the Editor:

We congratulate Bishop and colleagues [1] for investigating the use of recombinant factor VIIa (rFVIIa) as a "rescue therapy for uncontrollable postoperative haemorrhage after cardiac surgery," which is a challenging and potentially life-threatening complication. However we would like to raise the following 3 issues:

1 Since the Food and Drug Administration (FDA) first licensed rFVIIa, in 1999 for use in patients with hemophilia, its use has been expanded to include bleeding in nonhemophilia patients, but without a clear consensus on the clinical indications [2]. Furthermore, concerns have been raised about its safety and efficacy in the . . . [Full Text of this Article]


Related Article

Reply
James Tatoulis
Ann. Thorac. Surg. 2007 83: 355-356. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
J. Tatoulis
Reply
Ann. Thorac. Surg., January 1, 2007; 83(1): 355 - 356.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.